Reveal Genomics and Ona collaborate on ONA-255 cancer treatment

Reveal Genomics has entered into a strategic alliance with Ona Therapeutics to accelerate the clinical development of a promising cancer treatment known as ONA-255. This innovative antibody-drug conjugate (ADC) is designed to enhance the effectiveness of cancer treatments across various types of solid tumors. The therapy represents a pioneering class of molecules targeting a novel ADC marker prevalent in many common solid tumors, offering new hope in cancer therapy.

The collaboration is particularly focused on leveraging the expertise of Reveal Genomics' Chief Scientific Officer and co-founder, Dr. Aleix Prat. Dr. Prat is renowned for his work in drug development and precision oncology. His significant contributions to this partnership include identifying the target for the therapy and producing critical preclinical data alongside Ona and Dr. Roger Gomis, which play a vital role in the clinical advancement of the treatment.

As part of the collaboration, Reveal Genomics will conduct a comprehensive molecular analysis of blood samples and tumors from the ONA-255 Phase I-II clinical trials. The company plans to use cutting-edge technologies and computational algorithms to uncover valuable molecular and genomic biomarkers. This in-depth analysis aims to provide insights into the immune microenvironment, tumor biology, and the mechanisms by which the therapy elicits a response.

The primary objectives of this research are to define specific populations that may benefit from the therapy, identify predictive biomarkers, and deepen the understanding of how the therapy works. This knowledge is crucial in improving the efficacy of ONA-255 and ensuring its success in treating patients with various solid tumor types.

Supporting this endeavor, Ona Therapeutics, in collaboration with Reveal's US branch, has secured a grant from the Centro para el Desarrollo Tecnológico y la Innovación (CDTI), part of the Spanish Ministry of Science and Innovation, along with universities dedicated to fostering technological development and innovation. This grant is part of the Pland e Recuperación, Transformación y Resiliencia (the Recovery, Transformation, and Resilience Plan), which is funded by the European Union's NextGenerationEU initiative. The financial backing will be instrumental in advancing the research and development activities associated with ONA-255.

According to Patricia Villagrasa, CEO and co-founder of Reveal Genomics, Ona Therapeutics is leading the charge in developing next-generation cancer treatments. She emphasized that this partnership represents a significant milestone in the integration of advanced diagnostic tools with cutting-edge therapeutic approaches. By incorporating biomarker science early in the drug development process, the collaboration seeks to bolster the strategic value of the treatment and ensure its success in clinical applications.

Furthermore, 2023 marked a pivotal year when Biocytogen Pharmaceuticals and Ona Therapeutics reached an agreement to collaborate on developing ADCs specifically for solid tumors. This agreement underscores the growing interest and investment in ADCs as a promising avenue for cancer treatment, highlighting the potential of ONA-255 as a groundbreaking therapy in the fight against cancer.